[Surgical approach for small bowel obstruction in the Russian Federation. National survey of surgeons].

Objective: To study surgical approach for small bowel obstruction (SBO) regarding national and international guidelines.

Material And Methods: Considering literature data, national and international guidelines and clinical practice, we have formulated 15 questions regarding surgical approach for non-neoplastic SBO. Questions were sent by e-mail to the members of the Russian Society of Surgeons.

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.

Objective And Design: The aim of this double-blind, placebo-controlled, phase III CORONA clinical trial was to evaluate the efficacy and safety of IL-6 receptor inhibitor levilimab (LVL) in subjects with severe COVID-19.

Subjects: The study included 217 patients. The eligible were men and non-pregnant women aged 18 years or older, hospitalized for severe COVID-19 pneumonia.

Timing of surgery, intestinal ischemia and other real factors of mortality in acute adhesive small bowel obstruction: a multiple-center study.

Objective: To analyze the factors of mortality in patients with acute adhesive small bowel obstruction (ASBO).

Material And Methods: A retrospective multiple-center study included 143 (85.6%) patients with ASBO out of 167 consecutive patients with small bowel obstruction for the period 2017-2019.

Functional and Biochemical Parameters of Erythrocytes during Mexicor Treatment in Posttraumatic Period after Experimental Blood Loss and Combined Traumatic Brain Injury.

Mexicor treatment (8 mg/kg body weight per day) during the posttraumatic period after concomitant traumatic brain injury and acute blood loss in rats increased electrophoretic mobility and concentration of 2,3-diphosphoglycerate, and reduced malondialdehyde content in erythrocytes. These changes improved hemodynamics and oxygen-transporting function of the blood. The most pronounced effects of Mexicor were observed at the early stages of posttraumatic period.

[Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].

Emoxyl (ruboxyl) is a product of chemical modification of daunorubicin mediated by a stable free radical. The drug was given to 63 patients with different malignancies stages I-II. Inhibition of hemopoiesis (leukopenia and thrombocytopenia) was identified as the dose-limiting toxicity level.